Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

MYSTERIOUS: 11 - What They Never Told You

5 “Strong Buy” Health Care Stocks to Buy This Week

Rising prevalence of chronic diseases and the increasing aging population are significant growth drivers of the healthcare industry. Moreover, growing investments in technological advancements should bode well for the industry. Thus, we think investing in quality healthcare stocks Johnson & Johnson (JNJ), Pfizer (PFE), Novo Nordisk (NVO), Bristol-Myers Squibb (BMY),…

StockNews.com

3 Health Care Stock Under $50 You Can Buy Today

The healthcare industry is anticipated to grow significantly in the coming years, thanks to strong demand amid rising chronic diseases, technological advancements, and rising healthcare spending. Therefore, we think fundamentally sound healthcare companies Pfizer (PFE), GSK Plc (GSK), and Teva Pharmaceutical (TEVA), which are currently trading under $50, could be…

StockNews.com

3 Stocks to Buy That Won’t Give You Any Headaches

The stock market has witnessed significant volatility amid the record high inflation and the Fed’s hawkish stance on it. Investors have been banking on healthcare stocks as they tend to hold up relatively well in such turbulent times. We think investing in quality healthcare stocks Johnson & Johnson (JNJ), Pfizer…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Everyone in Their 30s Should Own These 2 Stocks

The stock market has been down following Fed Chair Jerome Powell’s Jackson Hole speech that signaled continued monetary policy tightening. We think in this current volatile backdrop, people planning their retirement savings in their 30s should invest in fundamentally sound dividend-paying stocks Pfizer (PFE) and Costco (COST). Read more….

StockNews.com

Fury over housing plans that 'threaten the whole identity' of Greater Manchester village

The region's long-term masterplans stipulates that sports pitches and facilities in the area should be ‘retained and significantly enhanced’ as part of a ‘high quality' development.

Manchester Evening News

2 Stocks That Are More Than COVID-19 Plays

While the COVID-19 pandemic benefitted Johnson & Johnson (JNJ) and Pfizer (PFE) significantly as their vaccines helped the world recover from the crisis, these stocks are more than just COVID-19 plays because of their strong product portfolio and pipeline. They are well-positioned to capitalize on the rising chronic diseases, an…

StockNews.com

What Are Whales Doing With Pfizer

Someone with a lot of money to spend has taken a bullish stance on Pfizer (NYSE:PFE). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

This Is What Whales Are Betting On Pfizer

A whale with a lot of money to spend has taken a noticeably bearish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 29 strange trades.

Benzinga

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ:INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. Incyte shares traded in a range of $71.38 to $72.98 on day volume of 1.25…

Benzinga

Is Pfizer a Buy Before New Omicron Boosters Roll Out?

Pharmaceutical giant Pfizer’s (PFE) omicron-targeted booster doses could soon be authorized this fall. The company has benefited largely from the pandemic and its vaccine rollouts. Now let’s find out if PFE is a Buy now as it prepares to roll out its booster doses….

StockNews.com

5 Income Stocks to Turn to When Times Are Tough

The S&P 500 is coming off its four-week win streak amid signals of cooling price increases. However, inflation is still running hot near a 40-year high, which might induce the Fed to continue its policy rate hikes. We think income stocks AbbVie (ABBV), Amgen (AMGN), Pfizer (PFE), Bristol-Myers Squibb (BMY),…

StockNews.com

2 Pharmaceutical Stocks That Could Outperform the Market in the Long Term

The pharmaceutical industry is growing rapidly with advancements in drug manufacturing and a paradigm shift to personalized medicines. Moreover, despite soaring prices, supportive fiscal policies are expected to keep consumer demand stable. Quality pharmaceutical stocks Pfizer (PFE) and Merck (MRK) have outperformed the broader market over the past year and…

StockNews.com

Check Out What Whales Are Doing With PFE

Benzinga

2 Stocks That Could Be Long-Term Winners for Investors

With the economy reporting two consecutive quarters of GDP decline, many analysts believe that the economy has already entered a recession. During periods of market uncertainty, investors should look for stocks that could win in the long run based on their strong fundamentals and solid growth prospects. We think Pfizer…

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Check Out What Whales Are Doing With PFE

Someone with a lot of money to spend has taken a bearish stance on Pfizer (NYSE:PFE). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

StockNews.com

3 High-Quality Stocks to Pick Up for the Second-Half

The bear market provides an opportunity for investors to buy shares of high-quality companies at attractive valuations. Below are 3 such stocks that investors should consider buying during this market correction: Elevance Health (ELVH), Pfizer (PFE), and Builders FirstSource (BLDR).

StockNews.com

2 Stocks Hedge Funds Have Been Buying up in 2022

Amid the bear market, hedge funds have been buying shares of Merck & Co. (MRK) and Pfizer (PFE). This, along with the strong fundamentals and growth prospects of these stocks, makes them good additions to your watchlist. Let’s discuss.

StockNews.com

Is Buying Pfizer Stock Right Now a Mistake?

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Undervalued Stocks to Add to Your Watchlist Right Now

The rising odds of a recession amid the Fed’s aggressive interest rate hikes to tame multi-decade high inflation are leading to heightened market volatility. However, staying invested amid such downturns is essential so one doesn’t miss out on long-term returns. We believe fundamentally sound stocks Pfizer (PFE), Broadcom (AVGO), and…

StockNews.com

Is Biotech Ready for Another Bull Run? 3 Stocks to Get in Ahead of the Crowd

The biotech industry flourished during the height of the COVID-19 pandemic and reported record revenues and earnings last year. Despite the market slowdown, the sector is poised for another bull run, given the continued global fight against COVID-19 and the increasing demand with an aging population. Popular biotech stocks Pfizer…

StockNews.com

As Covid Cases Decline, is it Time to Drop Pfizer?

Leading drug maker Pfizer (PFE) experienced robust growth over the past year primarily based on the growing demand for its Covid vaccine. However, as Covid cases decline, will the company be able to maintain its growth trajectory? Let’s find out.

Benzinga

This Analyst Says US Government Buying More COVID-19 Vaccines At Higher Prices

Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced a new COVID-19 vaccine supply agreement with the U.S. government. SVB Leerink says that the new contract implies the price per Comirnaty dose is ~$30.50. Comirnaty U.S. pricing per dose has increased from $19.50 (2020 contracts), to $24 (+23%; 2021 contract), and now to ~$30.50 (+27%). The analysts…

Benzinga

Pfizer Seeks Complete Approval For Paxlovid For High Risk COVID-19 Patients

Pfizer Inc (NYSE:PFE) has submitted a new drug application to the FDA for the approval of Paxlovid for patients at high risk for progression to severe illness from COVID-19. Paxlovid is currently authorized for emergency use to treat mild-to-moderate COVID-19 in adults and pediatric patients at high risk for progression to severe COVID-19,…

Benzinga

US Government Calls For Additional Doses Of Pfizer/BioNTech COVID-19 Vaccine

Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) have announced a new vaccine supply agreement with the U.S. government. Under the agreement, the U.S. government will receive 105 million doses (30 µg, 10 µg and 3 µg). This may include adult omicron-adapted COVID-19 vaccines, subject to the FDA authorization. The doses are planned to be delivered…

Benzinga

Roivant, Pfizer Unveil Latest Spinout Focused On Autoimmune Diseases

Roivant Sciences Ltd (NASDAQ:ROIV) and Pfizer Inc (NYSE:PFE) unveiled Priovant Therapeutics, dedicated to developing and commercializing novel therapies for autoimmune diseases. Priovant was established in September 2021 through a transaction between Roivant and Pfizer. Pfizer licensed oral and topical brepocitinib's global development rights and US and Japan commercial rights to Priovant. Pfizer holds a 25%…

1 … 10 11 12 13

People

Dipanjan BanchurSince

722 stories

Jaimini DesaiJaimini

62 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.